103422-25-9

Upstream product

• 50-07-7 mitomycin C 
• 4055-39-4 mitomycin A 

Downstream Products

• 99745-88-7 trans-1-hydroxy-2,7-diaminomitosene 
• 98462-75-0 2β,7-Diamino-1β-hydroxymitosene 
• 106471-85-6 1α-deuterio-2,7-diaminomitosene 
• 92695-32-4 2,7-Diaminomitosene 
• 1207530-65-1 C₁₅H₁₄N₄O₆ 

Relevant academic research and scientific papers

Studies on the reactivity of reductively activated mitomycin C

Mitomycin C (1a), a clinically significant antineoplastic antiobiotic, is considered to be the prototype of bioreductive alkylating agents. It has been reported that, in the absence of DNA, reductive activation of 1a furnished both solvolytic C(1) electro

7-Aminoaziridinomitosenes: Synthesis, Structure, and Chemistry

7-Aminoleucoaziridinomitosene (2a) has been proposed as a key intermediate in the reductive activation process for the antineoplastic agent, mitomycin C (1a).Little is known about 2a and its oxidised equivalent, 7-aminoaziridinomitosene (3a).An expedient electrochemical procedure for 3a and the corresponding N-methyl analogue 3b has been developed.NMR spectral studies of 3a in DMF-d7 and DMSO-d6 provided important information concerning the solution-state structure for this adduct.Factors controlling the aziridine ring-opening process under reductive and nonreductive conditions have been determined, as well as evidence for the intermediacy of 2a in the reductive activation cascade of 1a.